*The following content is generated by AI and is for reference only.
Travoprost is a synthetic prostaglandin F2α analog widely utilized in ophthalmology for the management of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Chemically, its molecular formula is C26H40O5, and it is identified by the CAS number 139788-38-2. The compound features a unique structure that enhances stability and selectivity compared to earlier generations of prostaglandins, minimizing systemic absorption while effectively targeting specific receptors in the eye.
The primary mechanism of action involves increasing uveoscleral outflow, the alternative drainage pathway for aqueous humor, thereby reducing IOP without significantly altering blood flow to the optic nerve. Clinical studies have consistently demonstrated that Travoprost provides potent IOP reduction, often achieving a 30% to 35% decrease from baseline when administered as a once-daily topical solution, typically in the evening. This efficacy makes it a first-line therapy in many global treatment guidelines.
Available commercially under various brand names such as Travatan Z, the medication is formulated as sterile eye drops containing preservatives like benzalkonium chloride in some versions, though preservative-free options exist for sensitive patients. Common side effects include conjunctival hyperemia, iris pigmentation changes which may become permanent, eyelash growth, and periorbital skin darkening. While generally well-tolerated, patients with a history of uveitis or cystoid macular edema require careful monitoring. Its pharmacokinetic profile ensures rapid onset with sustained effect throughout the dosing interval. As a cornerstone in glaucoma care, Travoprost offers a crucial tool for preventing vision loss caused by optic nerve damage, balancing high therapeutic efficacy with a manageable safety profile for long-term adherence.